`
`Paper No. _____
`Date Filed: April 5, 2016
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`MYLAN LABORATORIES LIMITED
`Petitioner,
`v.
`AVENTIS PHARMA S.A.
`Patent Owner.
`________________
`
`Case IPR2016-00712
`U.S. Patent No. 8,927,592
`________________
`
`
`
`AVENTIS PHARMA S.A.
`MANDATORY NOTICES – 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, Aventis Pharma S.A. (the “Patent Owner”), as
`
`indicated by the assignment recorded at Reel/Frame 028992/0505 submits the
`
`following Mandatory Notices.
`
`Real Party-In-Interest (37 C.F.R. § 42.8 (b)(1)):
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the real party-in-
`
`interest is Aventis Pharma S.A. (the “Patent Owner”). Sanofi, the ultimate parent
`
`company of Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, an affiliate of
`
`Aventis Pharma S.A. are also real parties-in-interest.
`
`Related Matters (37 C.F.R. § 42.8 (b)(2)):
`
`On May 15, 2015, Patent Owner, along with Sanofi-Aventis U.S. LLC and
`
`Sanofi (collectively “Sanofi”) filed a complaint averring that Petitioner’s
`
`Abbreviated New Drug Application (“ANDA”) No. 207381 concerning a proposed
`
`drug product, cabazitaxel injection [60 mg/1.5 mL] [40 mg/mL], infringes U.S.
`
`Patent No. 8,927,592 (“the ’592 patent”) under 35 U.S.C. § 271(e)(2). That
`
`lawsuit is pending in the United States District Court for the District of New Jersey
`
`and is captioned: Sanofi-Aventis U.S. LLC et al. v. Mylan Laboratories Limited,
`
`Civil Action No. 15-03392 (MAS)(LHG). Sanofi also filed additional complaints
`
`alleging infringement of the ’592 patent that are all pending in the United States
`
`District Court for the District of New Jersey and are captioned: Sanofi-Aventis U.S.
`
`LLC et al. v. Fresenius Kabi USA, LLC, C. A. No. 15-02631 (MAS)(LHG); Sanofi-
`
`
`
`- 2 -
`
`
`
`
`
`
`Aventis U.S. LLC et al. v. Accord Healthcare, Inc., C. A. No. 15-02520
`
`(MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. BPI Labs, LLC et al., C. A. No.
`
`15-02521 (MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. Apotex Corp. et al., C.
`
`A. No. 15-01835 (MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. Breckenridge
`
`Pharmaceutical, Inc., C. A. No. 15-01836 (MAS)(LHG); Sanofi-Aventis U.S. LLC
`
`et al. v. Actavis LLC et al., C. A. No. 15-03107 (MAS)(LHG); Sanofi-Aventis U.S.
`
`LLC et al. v. Dr. Reddy’s Laboratories, Inc. et al., C. A. No. 15-02522
`
`(MAS)(LHG); and Sanofi-Aventis U.S. LLC et al. v. Glenmark Pharmaceuticals,
`
`Inc., USA et al., C. A. No. 15-02523 (MAS)(LHG). Also, the following patent
`
`applications claim the benefit of the priority of the filing date of the subject patent:
`
`U.S. Patent Application Nos. 14/575,566 and 14/575,578.
`
`Designation of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)):
`
`Lead counsel is Dominick A. Conde (Reg. No. 33,856). William E.
`
`Solander, Jason A. Leonard, and Whitney L. Meier (Reg. No. 69,923) are
`
`designated as back-up counsel. William E. Solander and Jason A. Leonard require
`
`pro hac vice admission to appear in this proceeding.
`
`A power of attorney from Aventis Pharma S.A. is being submitted with this
`
`- 3 -
`
`
`Notice.
`
`
`
`
`
`
`
`
`
`Service Information (37 C.F.R. § 42.8(b)(4)):
`
`Aventis Pharma S.A. may be served by postal mailing, hand-delivery,
`
`telephone or facsimile as follows:
`
`Dominick A. Conde
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`
`1290 Avenue of the Americas
`
`New York, NY 10104-3800
`
`Telephone:
`
`(212) 218-2100
`
`Facsimile:
`
`(212) 218-2200
`
`Aventis Pharma S.A. may be served electronically using the following e-
`
`mail addresses:
`
`
`
`
`
`
`
`
`
`dconde@fchs.com (lead counsel)
`
`wsolander@fchs.com (back-up counsel)
`
`jleonard@fchs.com (back-up counsel)
`
`wmeier@fchs.com (back-up counsel)
`
`
`
`- 4 -
`
`
`
`
`
`
`Any questions concerning this paper may be directed to lead counsel listed
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER & SCINTO
`Tel: (212) 218-2100
`
`Attorneys for Patent Owner,
`Aventis Pharma S.A.
`
`Back-up Counsel:
`William E. Solander (pro hac vice
`pending)
`Jason A. Leonard (pro hac vice
`pending)
`Whitney L. Meier (Reg. No. 69,923)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`(212) 218-2100
`
`
`- 5 -
`
`
`below.
`
`April 5, 2016
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the Patent Owners’ Mandatory Notices Under 37
`
`C.F.R. § 42.8(a)(2) and Power of Attorney were served on April 5, 2016 by
`
`causing them to be sent by email to counsel for Petitioner at the following email
`
`addresses:
`
`sparmelee@wsgr.com
`
`mrosato@wsgr.com
`
`jmills@wsgr.com
`
`April 5, 2016
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`
`- 6 -